- Lexaria Bioscience Corp. announced a registered direct offering to sell approximately **2.67 million shares** of common stock at **$1.50 per share**, expecting to raise about **$4 million** for working capital and general corporate purposes.  **[1348362_9508d64377f44c5da2972a79eb1dfc0c]** 
- The offering also includes unregistered warrants exercisable at **$1.37 per share**.  **[1348362_9508d64377f44c5da2972a79eb1dfc0c]**  This follows the termination of a prior sales agreement that had raised only **$38,236**.  **[1348362_9508d64377f44c5da2972a79eb1dfc0c]** 
- Despite facing significant financial challenges, including a **negative operating margin of -1849.84%** and a **3-year revenue decline rate of -39.2%**, Lexaria's shares **surged 32%** in premarket trading.  **[1348362_9508d64377f44c5da2972a79eb1dfc0c]** 
- The company maintains a strong balance sheet with a **current ratio of 3.9** and a **low debt-to-equity ratio of 0.02**, and analysts currently rate the stock as a **Buy** with a **$4.00 price target**.  **[1348362_9508d64377f44c5da2972a79eb1dfc0c]**

Lexaria Bioscience (LEXX)